FC
QGEN icon

Fairpointe Capital’s Qiagen QGEN Stock Holding History

Fairpointe Capital’s Portfolio QGEN Stock Details QGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$352K Buy
+6,834
New +$375K 0.53% 53
2020
Q1 		– Sell
-244,549
Closed -$8.77M – 81
2019
Q4 		$8.77M Buy
+244,549
New +$9.09M 0.67% 41

Other funds holding QGEN

Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fairpointe Capital's QGEN Position: Q1 2021 in Review

Fairpointe Capital opened a new position in Qiagen (QGEN) in Q1 2021: 6,834 shares worth $352K. The stake represents 0.53% of the portfolio and ranks #53 among its holdings. This is a return to the name: Fairpointe Capital previously reported a position in QGEN as recently as Q4 2019.

Fairpointe Capital first reported a position in QGEN in Q4 2019 and has held it in 2 quarters since. The position peaked at $8.77M in Q4 2019. 275 funds tracked by Wall St. Rank hold QGEN as of Q1 2021.

  • Fairpointe Capital held 6,834 shares of Qiagen worth $352K as of Q1 2021.
  • Qiagen was a new Fairpointe Capital position in Q1 2021.
  • Qiagen made up 0.53% of Fairpointe Capital's portfolio in Q1 2021, its #53 holding.
  • Fairpointe Capital first reported a position in Qiagen in Q4 2019 and has held it in 2 quarters since.
  • Fairpointe Capital's Qiagen position peaked at $8.77M in Q4 2019.
  • 275 funds tracked by Wall St. Rank held Qiagen as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.